<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:chebi fb="0" ids="17230">Homocysteine</z:chebi> is an emerging risk factor for cardiovascular and nondiabetic ocular <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">vaso-occlusive diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>However, studies of the relationship between <z:chebi fb="0" ids="17230">homocysteine</z:chebi> and diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> have reported inconsistent results </plain></SENT>
<SENT sid="2" pm="."><plain>The purpose of this study was to evaluate the relationship between plasma total <z:chebi fb="0" ids="17230">homocysteine</z:chebi> concentration and diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESEARCH DESIGN AND METHODS: We assessed the <z:chebi fb="0" ids="17230">homocysteine</z:chebi>-<z:hpo ids='HP_0000488'>retinopathy</z:hpo> relationship in 168 men and women with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in a community-based, cross-sectional study </plain></SENT>
<SENT sid="4" pm="."><plain>We photodocumented diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> status and measured plasma total <z:chebi fb="0" ids="17230">homocysteine</z:chebi> concentration using a commercial fluorescence polarization immunoassay enzymatic kit </plain></SENT>
<SENT sid="5" pm="."><plain>Data for selected clinical/demographic variables and established risk factors for diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> were obtained from fasting blood samples and an interviewer-assisted lifestyle questionnaire </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: A higher mean plasma total <z:chebi fb="0" ids="17230">homocysteine</z:chebi> concentration was observed in diabetic individuals with <z:hpo ids='HP_0000488'>retinopathy</z:hpo> than in those without <z:hpo ids='HP_0000488'>retinopathy</z:hpo> (11.5 mumol/l [95% CI 10.4-12.5] vs. 9.6 mumol/l [9.1-10.2], P = 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, the relationship between <z:chebi fb="0" ids="17230">homocysteine</z:chebi> and diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> was not explained by <z:hpo ids='HP_0000082'>renal dysfunction</z:hpo> and was independent of the other major risk factors for diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> (duration of <z:mp ids='MP_0002055'>diabetes</z:mp>, A1C, and systolic blood pressure) and determinants of higher <z:chebi fb="0" ids="17230">homocysteine</z:chebi> concentrations (age, sex, and red cell <z:chebi fb="3" ids="37445">folate</z:chebi>) (odds ratio 1.20 [95% CI 1.023-1.41], P = 0.024) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Plasma total <z:chebi fb="0" ids="17230">homocysteine</z:chebi> concentration may be a useful biomarker and/or a novel risk factor for increased risk of diabetic <z:hpo ids='HP_0000488'>retinopathy</z:hpo> in people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>